JP2017503482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503482A5 JP2017503482A5 JP2016536893A JP2016536893A JP2017503482A5 JP 2017503482 A5 JP2017503482 A5 JP 2017503482A5 JP 2016536893 A JP2016536893 A JP 2016536893A JP 2016536893 A JP2016536893 A JP 2016536893A JP 2017503482 A5 JP2017503482 A5 JP 2017503482A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cytomegalovirus
- nucleotide sequence
- antigenic fragment
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US61/911,135 | 2013-12-03 | ||
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| US62/055,699 | 2014-09-26 | ||
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Division JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503482A JP2017503482A (ja) | 2017-02-02 |
| JP2017503482A5 true JP2017503482A5 (https=) | 2018-01-18 |
| JP6818551B2 JP6818551B2 (ja) | 2021-01-20 |
Family
ID=52232138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Active JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (https=) |
| EP (2) | EP3904522A1 (https=) |
| JP (2) | JP6818551B2 (https=) |
| CN (2) | CN115058452A (https=) |
| AU (2) | AU2014359276B2 (https=) |
| CA (1) | CA2932318C (https=) |
| CY (1) | CY1124288T1 (https=) |
| DK (1) | DK3077519T3 (https=) |
| ES (1) | ES2868427T3 (https=) |
| HR (1) | HRP20211015T1 (https=) |
| HU (1) | HUE054579T2 (https=) |
| LT (1) | LT3077519T (https=) |
| PL (1) | PL3077519T3 (https=) |
| PT (1) | PT3077519T (https=) |
| RS (1) | RS61993B1 (https=) |
| SI (1) | SI3077519T1 (https=) |
| WO (1) | WO2015082570A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CN115058452A (zh) * | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| LT3218504T (lt) | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| RS63546B1 (sr) * | 2015-11-12 | 2022-09-30 | Hookipa Biotech Gmbh | Čestice arenavirusa kao vakcine protiv kancera |
| US11260090B2 (en) | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| EP3534943A2 (en) | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| US11572389B2 (en) * | 2017-01-27 | 2023-02-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| JP2020516291A (ja) | 2017-04-14 | 2020-06-11 | レジェンクスバイオ インコーポレーテッド | ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸−２−スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療 |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CN112512569A (zh) | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CA3116175A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| KR102609106B1 (ko) * | 2018-12-10 | 2023-12-05 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신 |
| JP7783631B2 (ja) * | 2019-11-07 | 2025-12-10 | ウニヴェルズィテート バーゼル | ベクターとしてのアレナウイルス |
| KR102837045B1 (ko) | 2020-06-09 | 2025-07-23 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| BR112023016075A2 (pt) | 2021-02-10 | 2023-11-21 | Regenxbio Inc | Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JP2607712B2 (ja) * | 1988-01-29 | 1997-05-07 | カイロン コーポレイション | 組換えｃｍｖ中和タンパク |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP1265916B1 (en) * | 2000-03-21 | 2005-12-21 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| CA2597921A1 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2604695B1 (en) | 2007-12-27 | 2022-11-16 | Universität Zürich | Replication-defective arenavirus vectors |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2012530500A (ja) * | 2009-06-26 | 2012-12-06 | ヴェクトライト バイオメディカ インコーポレイテッド | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 |
| SG189176A1 (en) * | 2010-10-15 | 2013-05-31 | Glaxosmithkline Biolog Sa | Cytomegalovirus gb antigen |
| CN103597098A (zh) * | 2011-01-07 | 2014-02-19 | 斯洛伐克生物科学公司 | 病毒诊断 |
| WO2012162428A1 (en) * | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| WO2013006838A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| ES2753138T3 (es) * | 2012-07-06 | 2020-04-07 | Glaxosmithkline Biologicals Sa | Complejos de proteínas de citomegalovirus |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| CN115058452A (zh) | 2013-12-03 | 2022-09-16 | 霍欧奇帕生物科技有限公司 | Cmv疫苗 |
| LT3218504T (lt) * | 2014-11-13 | 2020-09-10 | Université De Geneve | Trijų segmentų arenavirusai kaip vakcinos vektoriai |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| RS63546B1 (sr) | 2015-11-12 | 2022-09-30 | Hookipa Biotech Gmbh | Čestice arenavirusa kao vakcine protiv kancera |
| US20190135875A1 (en) | 2016-05-18 | 2019-05-09 | Hookipa Biotech Gmbh | Tri-segmented pichinde viruses as vaccine vectors |
| EP3534943A2 (en) | 2016-11-04 | 2019-09-11 | Hookipa Biotech GmbH | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| AU2018247958A1 (en) | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| JP7783631B2 (ja) | 2019-11-07 | 2025-12-10 | ウニヴェルズィテート バーゼル | ベクターとしてのアレナウイルス |
| MX2022014725A (es) | 2020-05-29 | 2023-02-09 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. |
-
2014
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503482A5 (https=) | ||
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| JP2021061848A5 (https=) | ||
| JP2021182922A5 (https=) | ||
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| TWI605124B (zh) | 新穎桿狀病毒載體及使用方法 | |
| US12064477B2 (en) | HPV vaccine | |
| Mitra-Kaushik et al. | Identification of a cytotoxic T-cell epitope on the recombinant nucleocapsid proteins of Rinderpest and Peste des petits ruminants viruses presented as assembled nucleocapsids | |
| JP2018536433A5 (https=) | ||
| JP2017522907A5 (https=) | ||
| JP2009540801A5 (https=) | ||
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| CN113930452B (zh) | 基于黑猩猩腺病毒载体的重组载体、腺病毒、2019新型冠状病毒疫苗及其制备方法 | |
| Smith et al. | The development of prophylactic and therapeutic EBV vaccines | |
| Small et al. | Viruses—From pathogens to vaccine carriers | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
| JP2019500320A5 (https=) | ||
| CN113226364A (zh) | 组合物和方法 | |
| US20230372474A1 (en) | Recombinant hvt and uses thereof | |
| WO2006009011A1 (ja) | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター | |
| WO2015024484A1 (zh) | 一种新型狂犬病疫苗及其制备方法 | |
| Galdiero et al. | SARS-CoV-2 vaccine development: where are we | |
| CN105219740A (zh) | 一种重组人3型腺病毒及制备方法和应用 |